Latest Share Chat

IN BRIEF: RTW Venture Fund takes part in Kyverna funding round

Wed, 26th Jan 2022 19:14

RTW Venture Fund Ltd - New York-based investor in life sciences, biopharmaceutical, and medical technology companies - Takes part in Series B financing round worth USD85 million into Kyverna Therapeutics Inc.

Kyverna is a cell therapy firm which is developing a new class of therapies for autoimmune and inflammatory disease.

Proceeds from the funding round will go towards the initiation of a phase two clinical trial for the company's lead asset KYV-101, scheduled for the first half of 2022.

Current stock price: USD1.50

12-month change: down 32%

By Dayo Laniyan; dayolaniyan@alliancenews.com

Related Shares

More News

15 May 2024 21:43

TRADING UPDATES: Future Metals celebrates state government grant

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

5 Apr 2024 12:14

RTW Biotech invests in cell and gene therapy company Obsidian

(Alliance News) - RTW Biotech Opportunities Ltd on Friday said it has backed cell and gene therapy-focused biotech Obsidian Therapeutics Inc.

2 Apr 2024 11:15

EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

20 Feb 2024 20:13

TRADING UPDATES: Franchise Brands sets targets, Cindrigo agrees loan

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

14 Feb 2024 19:53

IN BRIEF: RTW Biotech Opportunities NAV increases 2.5% in January

RTW Biotech Opportunities Ltd - London-based venture capital firm focused on biotechnology companies - Says net asset value per share at January 31 wa...